- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 07.11. | GHO and Ampersand Capital to acquire Avid Bioservices | ||
| 07.11. | EMA approves Sanofi/Regeneron's Dupixent for young EoE patients | ||
| 07.11. | DeepMind Nobel Prize winner says AI will have "electricity" type of impact | ||
| 06.11. | Zentiva voices UWWTD concerns as EU grants approval | ||
| 06.11. | Intra-Cellular bolsters Caplyta data with another Phase III win | ||
| 06.11. | Top 20 biopharmas' market cap rises 2% in Q3 2024 amid flurry of drug approvals | ||
| 06.11. | Strong Wegovy revenue growth for Novo Nordisk but shares dip | ||
| 06.11. | GSK CEO addresses declining trust in vaccines following Trump re-election | ||
| 06.11. | Tevogen Bio partners Microsoft for HPV treatment | ||
| 06.11. | Trump triumphs but impact on healthcare industry remains unclear | ||
| 06.11. | Nxera Pharma and Antiverse to design antibodies targeting GPCRs | ||
| 06.11. | GSK's RSV vaccine approved in Canada for adults aged 50 to 59 | ||
| 05.11. | Vertex shares up after full-year product revenue guidance boost | ||
| 05.11. | NLS Pharmaceutics and Kadimastem stocks soar following merger agreement | ||
| 05.11. | Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RA | ||
| 05.11. | FDA approves Journey Medical's rosacea treatment Emrosi | ||
| 05.11. | Nektar Therapeutics to sell Alabama facility to Ampersand | ||
| 05.11. | Oxford Nanopore and UK to develop pathogen surveillance system | ||
| 05.11. | EMA accepts Alvotech and Advanz Pharma's AVT05 MAA | ||
| 05.11. | How hybrid models and tech are shaping the future of clinical research | ||
| 05.11. | Syndax agrees funding with Royalty Pharma for Niktimvo US sales | ||
| 05.11. | Injectables manufacturing ushers in a new era of accessibility | ||
| 04.11. | Disc teases potential NDA for rare skin disorder drug | ||
| 04.11. | US Election: In close race, tiny Senate majority, not President, will hold power | ||
| 04.11. | Prokarium bolsters IP portfolio with two new US patents |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
